Dr Lau on the Temportal Patterns of irAEs Associated With the Stride Regimen in HCC


George Lau, MD, FRCP, FAASLD, discusses clinical implications for the use of dual checkpoint inhibition in HCC based on an analysis of immune-related adverse effects seen with the STRIDE regimen in the phase 3 HIMALAYA trial.

George Lau, MD, FRCP, FAASLD, chairman, senior consultant, Gastroenterology and Hepatology, the Humanity and Health Medical Group, discusses clinical implications for the use of dual checkpoint inhibition in HCC based on an analysis of immune-related adverse effects (IrAEs) seen with the single tremelimumab regular interval durvalumab (STRIDE) regimen in the phase 3 HIMALAYA trial (NCT03298451).

An exploratory post hoc analysis evaluated the frequency and timing of irAEs in relation to treatment with tremelimumab (Imjudo) plus durvalumab (Imfinzi) in patients with unresectable hepatocellular carcinoma (HCC), Lau begins.

Safety data from the initial read-out of the HIMILAYA trial showed that both the STRIDE regimen and the monotherapy had a manageable safety profile. However, the safety profile of the STRIDE regimen is differentiated from other available immune checkpoint inhibitor (ICI) combinations, necessitating an investigation of when and how long immune-related toxicities occurred during the treatment course.

Of the original 1171 patients enrolled on the study, safety was assessed in those who had received 1 or more doses of tremelimumab (Imjudo) plus durvalumab (Imfinzi) at 300 and 500 mg, respectively, or were given durvalumab alone. IrAEs were defined as AEs of special interest associated with drug exposure and wereconsistent with an immune-mediated mechanism of action for which no alternate etiology was clear. The frequency of irAEs and category of AEs were recorded at several time points after treatment initiation, with a data cut off of August 27, 2021.

Results presented at the 2023 ASCO Annual Meeting demonstrated that any-grade irAEs occurred more frequently with the STRIDE regimen vs durvalumab alone. However, the majority of irAEs associated with the STRIDE regimen occurred within the first 3 months of treatment, were low grade, and were manageable, Lau states.

Moreover, the timing and severity of toxicities in the STRIDE group were comparable between the combination and monotherapy groups, despite the higher frequency of toxicities seen with the STRIDE regimen. This outcome was also consistent with previous studies of dual ICI therapy vs single-agent ICIs.

These data have addressed a major concern regarding whether a dual checkpoint inhibitor regimen for patients with HCC would overaugment immune responses and lead to worsened irAEs, Lau concludes.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD